- Home
- KLTR vs DRUG Comparison
KLTR vs DRUG Comparison
Compare KLTR & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTR
- DRUG
- Stock Information
- Founded
- KLTR 2006
- DRUG 2019
- Country
- KLTR United States
- DRUG United States
- Employees
- KLTR N/A
- DRUG N/A
- Industry
- KLTR EDP Services
- DRUG Pharmaceuticals and Biotechnology
- Sector
- KLTR Technology
- DRUG Health Care
- Exchange
- KLTR Nasdaq
- DRUG Nasdaq
- Market Cap
- KLTR 302.6M
- DRUG 345.6M
- IPO Year
- KLTR 2021
- DRUG N/A
- Fundamental
- Price
- KLTR $1.68
- DRUG $44.88
- Analyst Decision
- KLTR Buy
- DRUG Strong Buy
- Analyst Count
- KLTR 3
- DRUG 9
- Target Price
- KLTR $2.83
- DRUG $81.67
- AVG Volume (30 Days)
- KLTR 264.1K
- DRUG 70.6K
- Earning Date
- KLTR 11-05-2025
- DRUG 08-11-2025
- Dividend Yield
- KLTR N/A
- DRUG N/A
- EPS Growth
- KLTR N/A
- DRUG N/A
- EPS
- KLTR N/A
- DRUG N/A
- Revenue
- KLTR $181,350,000.00
- DRUG N/A
- Revenue This Year
- KLTR $3.43
- DRUG N/A
- Revenue Next Year
- KLTR $2.96
- DRUG N/A
- P/E Ratio
- KLTR N/A
- DRUG N/A
- Revenue Growth
- KLTR 2.56
- DRUG N/A
- 52 Week Low
- KLTR $1.23
- DRUG $0.94
- 52 Week High
- KLTR $2.82
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- KLTR 55.44
- DRUG 54.95
- Support Level
- KLTR $1.67
- DRUG $39.70
- Resistance Level
- KLTR $1.74
- DRUG $49.38
- Average True Range (ATR)
- KLTR 0.09
- DRUG 3.11
- MACD
- KLTR 0.03
- DRUG -0.07
- Stochastic Oscillator
- KLTR 75.61
- DRUG 56.74
About KLTR Kaltura Inc.
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.